New hope for rare tumors: tarlatamab trial opens

NCT ID NCT06788938

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical carcinoid tumor carcinoid tumor digestive system neuroendocrine neoplasm large cell neuroendocrine carcinoma neoplasm small cell carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TUMORS DLL3-EXPRESSING TUMORS

Contacts and locations

Show contact details

Locations

UC Davis Comprehensive Cancer Center
RECRUITING

Davis, California, 95817, United States
UC San Diego Moores Cancer Center
RECRUITING

San Diego, California, 92093, United States
UCI Health Chao Family Comprehensive Cancer Center
RECRUITING

Irvine, California, 92612, United States
University of California at Los Angeles
RECRUITING

Los Angeles, California, 90095, United States

Contact Email: •••••@•••••
University of California at San Francisco
RECRUITING

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.